CytoDyn Reports Leronlimab Boosts PD-L1 and Extends Survival in Metastatic Triple-Negative Breast Cancer

Reuters12-08

CytoDyn Reports Leronlimab Boosts PD-L1 and Extends Survival in Metastatic Triple-Negative Breast Cancer

CytoDyn Inc., a clinical-stage oncology company, announced updated results from a retrospective follow-up analysis involving 28 women with metastatic triple-negative breast cancer (mTNBC) who participated in three leronlimab clinical trials. The findings, which will be presented as a poster at the San Antonio Breast Cancer Symposium on December 12, 2025, indicate that leronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cells. Among patients who demonstrated significant PD-L1 induction and subsequently received immune checkpoint inhibitors, all remain alive after a median of 60.9 months, with three showing no evidence of disease. No dose-limiting toxicities were observed, and no patients withdrew due to treatment-related adverse events. A copy of the presentation will be made available on CytoDyn's website after the symposium.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoDyn Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598183-en) on December 08, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589355624?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 21:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589355624","market":"fut","top_or_hot":-1,"title":"CytoDyn Reports Leronlimab Boosts PD-L1 and Extends Survival in Metastatic Triple-Negative Breast Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CytoDyn Reports Leronlimab Boosts PD-L1 and Extends Survival in Metastatic Triple-Negative Breast Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CYDY\">CytoDyn Inc.</a>, a clinical-stage oncology company, announced updated results from a retrospective follow-up analysis involving 28 women with metastatic triple-negative breast cancer (mTNBC) who participated in three leronlimab clinical trials. The findings, which will be presented as a poster at the San Antonio Breast Cancer Symposium on December 12, 2025, indicate that leronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cells. Among patients who demonstrated significant PD-L1 induction and subsequently received immune checkpoint inhibitors, all remain alive after a median of 60.9 months, with three showing no evidence of disease. No dose-limiting toxicities were observed, and no patients withdrew due to treatment-related adverse events. A copy of the presentation will be made available on CytoDyn's website after the symposium.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoDyn Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598183-en) on December 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CytoDyn Reports Leronlimab Boosts PD-L1 and Extends Survival in Metastatic Triple-Negative Breast Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCytoDyn Reports Leronlimab Boosts PD-L1 and Extends Survival in Metastatic Triple-Negative Breast Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-08 21:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CytoDyn Reports Leronlimab Boosts PD-L1 and Extends Survival in Metastatic Triple-Negative Breast Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CYDY\">CytoDyn Inc.</a>, a clinical-stage oncology company, announced updated results from a retrospective follow-up analysis involving 28 women with metastatic triple-negative breast cancer (mTNBC) who participated in three leronlimab clinical trials. The findings, which will be presented as a poster at the San Antonio Breast Cancer Symposium on December 12, 2025, indicate that leronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cells. Among patients who demonstrated significant PD-L1 induction and subsequently received immune checkpoint inhibitors, all remain alive after a median of 60.9 months, with three showing no evidence of disease. No dose-limiting toxicities were observed, and no patients withdrew due to treatment-related adverse events. A copy of the presentation will be made available on CytoDyn's website after the symposium.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoDyn Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598183-en) on December 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3QW5Z07.USD","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL7VrqfZ:1","article_id":"2589355624","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589355624","pubTimestamp":1765200658,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CytoDyn Inc., a clinical-stage oncology company, announced updated results from a retrospective follow-up analysis involving 28 women with metastatic triple-negative breast cancer  who participated in three leronlimab clinical trials. The findings, which will be presented as a poster at the San Antonio Breast Cancer Symposium on December 12, 2025, indicate that leronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cells. Among patients who demonstrated significant PD-L1 induction and subsequently received immune checkpoint inhibitors, all remain alive after a median of 60.9 months, with three showing no evidence of disease. No dose-limiting toxicities were observed, and no patients withdrew due to treatment-related adverse events. A copy of the presentation will be made available on CytoDyn's website after the symposium.Disclaimer: This news brief was created by Public Technologies  using generative artificial int","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","NDAQ":"纳斯达克OMX交易所","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","BK4585":"ETF&股票定投概念","BK4139":"生物科技","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4112":"金融交易所和数据","CYDY":"CytoDyn Inc."},"translate_title":"CytoDyn报告Leronlimab增强PD-L1并延长转移性三阴性乳腺癌的生存期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CYDY":0.9,"NDAQ":0.9},"content_text":"CytoDyn Reports Leronlimab Boosts PD-L1 and Extends Survival in Metastatic Triple-Negative Breast Cancer\n    \n\nCytoDyn Inc., a clinical-stage oncology company, announced updated results from a retrospective follow-up analysis involving 28 women with metastatic triple-negative breast cancer (mTNBC) who participated in three leronlimab clinical trials. The findings, which will be presented as a poster at the San Antonio Breast Cancer Symposium on December 12, 2025, indicate that leronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cells. Among patients who demonstrated significant PD-L1 induction and subsequently received immune checkpoint inhibitors, all remain alive after a median of 60.9 months, with three showing no evidence of disease. No dose-limiting toxicities were observed, and no patients withdrew due to treatment-related adverse events. A copy of the presentation will be made available on CytoDyn's website after the symposium.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoDyn Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598183-en) on December 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589355624","isCrawlerRequest":true}